More on JNJ
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $258.45 |
|
|||
| Open | $258.45 | ||||
| 52 Wk High | $126.07 | ||||
| 52 Wk Low | $94.28 | ||||
| Day High | $258.45 | ||||
| Day Low | $258.45 | ||||
| P/E | 53.73 | ||||
| EPS | $4.81 | ||||
| Volume | 7,133 | ||||
- Johnson & Johnson (JNJ) call put ratio 1.6 calls to 1 put into quarter results
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
- Johnson & Johnson (JNJ) PT Raised to $290 at RBC Capital
- J&J releases 2-year icotrokinra data for hard-to-treat plaque psoriasis
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic ther
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
- Johnson & Johnson (JNJ) PT Raised to $13 at JPMorgan
- J&J presents two-year IMAAVY data in adolescent myasthenia gravis
- Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
Entities mentioned with JNJ
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
